Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 2

Современные подходы к медикаментозной коррекции генитоуринарного менопаузального синдрома
П.В. Козлов, Ю.Э. Доброхотова, И.Ю. Ильина

Список литературы

1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause (New York, N.Y.) 2013 Sep;20(9):888-902; quiz 903-4.
2. Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 2016 Jan;83:40-4.
3. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. The Journal of Sexual Medicine 2013 Jul;10(7):1790-9.
4. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. American Journal of Obstetrics & Gynecology 2004 May;190(5):1272-7.
5. Hillier SL, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clinical Infectious Diseases 1997 Sep;25(Suppl 2):S123-6.
6. Gorodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women. Menopause (New York, N.Y.) 2007 Nov-Dec;14(6):1012-9.
7. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause (New York, N.Y.) 2020 Sep;27(9):976-92.
8. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016 Apr;19(2):151-61.
9. Shifren JL, Zincavage R, Cho EL, Magnavita A, Portman DJ, Krychman ML, Simon JA, Kingsberg SA, Rosen RC. Women’s experience of vulvovaginal symptoms associated with menopause. Menopause (New York, N.Y.) 2018;26:341-9.
10. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause (New York, N.Y.) 2014 Oct;21(10):1063-8.
11. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstetrics & Gynecology 2011 Apr;117(4):922-7.
12. Gliniewicz K, Schneider GM, Ridenhour BJ, Williams CJ, Y, Farage MA, Miller K, Forney LJ. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Frontiers in Microbiology 2019 Feb;10:193.
13. Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, Brambilla E, Bosoni D, Cassani C, Gardella B. Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging in women. Frontiers in Endocrinology (Lausanne) 2019 Aug;10:561.
14. Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs & Aging 2019 Oct;36(10):897-908.
15. Buena de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause (New York, N.Y.) 2011 Mar;18(3):262-6.
16. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. Oncology (Williston Park, N.Y.) 2017 Oct;31(10):726-9.
17. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause (New York, N.Y.) 2013 Feb;20(2):162-8.
18. Kaunitz A.M. Sexual dysfunction with aromatase inhibitor therapy: an underestimated problem? NEJM Journal Watch. Women’s Health 2013 Feb;5-6.
19. Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014 Aug;17(4):342-7.
20. Bradford A. Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause (New York, N.Y.) 2013 Feb;20(2):128-9.
21. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsȁ9 Group. Quality of life of postmenopausal women in the ATAC (‘‘Arimidex’’, tamoxifen alone or in combination) trial after completion of 5 years’ adjuvant treatment for early stage breast cancer. Breast Cancer Research and Treatment 2006 Dec;100(3):273-84.
22. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. The Journal of Sexual Medicine 2017 Mar;14(3):413-24.
23. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause (New York, N.Y.) 2012 Jun;19(6):630-5.
24. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas M, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics, Gynecology and Reproductive Biology 2018 Oct;229:45-56.
25. Министерство здравоохранения РФ; Российское общество акушеров-гинекологов; Российская ассоциация по менопаузе. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. МКБ 10: N95.1. Возрастная категория: взрослые. Год утверждения: 2016 (пересмотр каждые 3 года). М., 2016. 45 с.
26. National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline. Draft for consultation, June 2015.
27. Beber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016 Apr;19(2):109-50.
28. Lee JS, Ettinger B, Stanczyk FZ, Vittinghoff E, Hanes V, Cauley JA, Chandler W, Settlage J, Beattie MS, Folkerd E, Dowsett M, Grady D, Cummings SR. Comparison of methods to measure low serum estradiol levels in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism 2006 Oct;91(10):3791-7.
29. Santen RJ, Pinkerton JV, Liu JH, Matsumoto AM, Lobo RA, Davis SR, Simon JA. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause (New York, N.Y.) 2020 Jun;27(6):614-24.
30. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics & Gynecology 2001;97:116-20.
31. Zilio Rech CM, Clapauch R, Bouskela E. Sexual function under adequate estrogen therapy in women after oophorectomy versus natural menopause. Journal of Women’s Health 2019 Aug;28(8):1124-32.
32. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017 Oct;177(10):1471-9.
33. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. The Journal of Sexual Medicine 2016 Mar;13(3):305-16.
34. Ju R, Ruan X, Xu X, Yang Y, Cheng J, Zhang L, Wang B, Qin S, Dou Z, Muek AO. Sexual dysfunction in Chinese women at different reproductive stages and the positive effect of hormone replacement therapy in the early postmenopause. The European Journal of Contraception & Reproductive Health Care 2021 Jun;26(3):246-54.
35. Galhardo CL, Soares JM Jr, Simoes RS, Haidar MA, de Lima GR, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clinical and Experimental Obstetrics & Gynecology 2006;33(2):85-9.
36. Heineman C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Canadian Journal of Microbiology 2005 Sep;51(9):777-81.
37. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause (New York, N.Y.) 2014 Mar;21(3):309-19.
38. Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause (New York, N.Y.) 2015 Jan;22(1):36-43.
39. Parish SJ, Gillespie JA. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Postgraduate Medicine 2017 Apr;129(3):340-51.
40. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. The Oncologist 2011;16(4):424-31.
41. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncology 2017 Mar;3(3):313-9.
42. Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause (New York, N.Y.) 2018 Jul;25(7):837-47.
43. Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R; other participants of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.) 2015 Dec;22(12):1289-95.
44. Maseroli E, Cellai I, Corno C, Rastrelli G, Filippi S, Comeglio P, Amoriello R, Ballerini C, Sarchielli E, Morelli A, Maggi M, Vignozzi L. Study of the anti-inflammatory effects of dihydrotestosterone in human vaginal smooth muscle cells. Endocrine Abstracts 2019;63:1123.
45. La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, Jędra R, Lordelo P, Favilli A. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Przeglad Menopauzalny 2019 Jun;18(2):116-22.
46. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the perior postmenopausal phase. The Cochrane Database of Systematic Reviews 2015 Jan;(1):CD011066.
47. Hersant B, SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause (New York, N.Y.) 2018 Oct;25(10):1124-30.
48. Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A – single vs. repeat injections. Toxicon 2013;63:83-7.
49. American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and U.S. Food and Drug Administration clearance. Position Statement. Washington, DC: ACOG. 2016. Available from: https://www.acog.org/Clinical-Guidanceand-Publications/Position/Statements/Fractional-Laser-Treatment-of-Vulvovaginal-Atrophy-and-US-Food-and-Drug-Administration-Clearance Accessed 2021 Aug 05.
50. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology. Female sexual dysfunction: ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists, number 213. Obstetrics & Gynecology 2019 Jul;134(1):e1-18.

References

1. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause (New York, N.Y.) 2013 Sep;20(9):888-902; quiz 903-4.
2. Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study. Maturitas 2016 Jan;83:40-4.
3. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. The Journal of Sexual Medicine 2013 Jul;10(7):1790-9.
4. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. American Journal of Obstetrics & Gynecology 2004 May;190(5):1272-7.
5. Hillier SL, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clinical Infectious Diseases 1997 Sep;25(Suppl 2):S123-6.
6. Gorodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women. Menopause (New York, N.Y.) 2007 Nov-Dec;14(6):1012-9.
7. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause (New York, N.Y.) 2020 Sep;27(9):976-92.
8. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016 Apr;19(2):151-61.
9. Shifren JL, Zincavage R, Cho EL, Magnavita A, Portman DJ, Krychman ML, Simon JA, Kingsberg SA, Rosen RC. Women’s experience of vulvovaginal symptoms associated with menopause. Menopause (New York, N.Y.) 2018;26:341-9.
10. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause (New York, N.Y.) 2014 Oct;21(10):1063-8.
11. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstetrics & Gynecology 2011 Apr;117(4):922-7.
12. Gliniewicz K, Schneider GM, Ridenhour BJ, Williams CJ, Y, Farage MA, Miller K, Forney LJ. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Frontiers in Microbiology 2019 Feb;10:193.
13. Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, Brambilla E, Bosoni D, Cassani C, Gardella B. Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging in women. Frontiers in Endocrinology (Lausanne) 2019 Aug;10:561.
14. Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs & Aging 2019 Oct;36(10):897-908.
15. Buena de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause (New York, N.Y.) 2011 Mar;18(3):262-6.
16. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. Oncology (Williston Park, N.Y.) 2017 Oct;31(10):726-9.
17. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause (New York, N.Y.) 2013 Feb;20(2):162-8.
18. Kaunitz A.M. Sexual dysfunction with aromatase inhibitor therapy: an underestimated problem? NEJM Journal Watch. Women’s Health 2013 Feb;5-6.
19. Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014 Aug;17(4):342-7.
20. Bradford A. Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. Menopause (New York, N.Y.) 2013 Feb;20(2):128-9.
21. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsȁ9 Group. Quality of life of postmenopausal women in the ATAC (‘‘Arimidex’’, tamoxifen alone or in combination) trial after completion of 5 years’ adjuvant treatment for early stage breast cancer. Breast Cancer Research and Treatment 2006 Dec;100(3):273-84.
22. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The women’s EMPOWER survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. The Journal of Sexual Medicine 2017 Mar;14(3):413-24.
23. Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause (New York, N.Y.) 2012 Jun;19(6):630-5.
24. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas M, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics, Gynecology and Reproductive Biology 2018 Oct;229:45-56.
25. Ministry of Healthcare of the Russian Federation; Russian Society of Obstetricians and Gynaecologists; Russian Association for Menopause. Clinical recommendations. Menopause and menopausal condition in woman. ICD 10: N95.1. Age category: adults. Year of approval: 2016. Moscow, 2016. 45 p. (In Russian).
26. National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline. Draft for consultation, June 2015.
27. Beber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016 Apr;19(2):109-50.
28. Lee JS, Ettinger B, Stanczyk FZ, Vittinghoff E, Hanes V, Cauley JA, Chandler W, Settlage J, Beattie MS, Folkerd E, Dowsett M, Grady D, Cummings SR. Comparison of methods to measure low serum estradiol levels in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism 2006 Oct;91(10):3791-7.
29. Santen RJ, Pinkerton JV, Liu JH, Matsumoto AM, Lobo RA, Davis SR, Simon JA. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause (New York, N.Y.) 2020 Jun;27(6):614-24.
30. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics & Gynecology 2001;97:116-20.
31. Zilio Rech CM, Clapauch R, Bouskela E. Sexual function under adequate estrogen therapy in women after oophorectomy versus natural menopause. Journal of Women’s Health 2019 Aug;28(8):1124-32.
32. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017 Oct;177(10):1471-9.
33. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. The Journal of Sexual Medicine 2016 Mar;13(3):305-16.
34. Ju R, Ruan X, Xu X, Yang Y, Cheng J, Zhang L, Wang B, Qin S, Dou Z, Muek AO. Sexual dysfunction in Chinese women at different reproductive stages and the positive effect of hormone replacement therapy in the early postmenopause. The European Journal of Contraception & Reproductive Health Care 2021 Jun;26(3):246-54.
35. Galhardo CL, Soares JM Jr, Simoes RS, Haidar MA, de Lima GR, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clinical and Experimental Obstetrics & Gynecology 2006;33(2):85-9.
36. Heineman C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Canadian Journal of Microbiology 2005 Sep;51(9):777-81.
37. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause (New York, N.Y.) 2014 Mar;21(3):309-19.
38. Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause (New York, N.Y.) 2015 Jan;22(1):36-43.
39. Parish SJ, Gillespie JA. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Postgraduate Medicine 2017 Apr;129(3):340-51.
40. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. The Oncologist 2011;16(4):424-31.
41. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncology 2017 Mar;3(3):313-9.
42. Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause (New York, N.Y.) 2018 Jul;25(7):837-47.
43. Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R; other participants of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause (New York, N.Y.) 2015 Dec;22(12):1289-95.
44. Maseroli E, Cellai I, Corno C, Rastrelli G, Filippi S, Comeglio P, Amoriello R, Ballerini C, Sarchielli E, Morelli A, Maggi M, Vignozzi L. Study of the anti-inflammatory effects of dihydrotestosterone in human vaginal smooth muscle cells. Endocrine Abstracts 2019;63:1123.
45. La Rosa VL, Ciebiera M, Lin LT, Fan S, Butticè S, Sathyapalan T, Jędra R, Lordelo P, Favilli A. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Przeglad Menopauzalny 2019 Jun;18(2):116-22.
46. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the perior postmenopausal phase. The Cochrane Database of Systematic Reviews 2015 Jan;(1):CD011066.
47. Hersant B, SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause (New York, N.Y.) 2018 Oct;25(10):1124-30.
48. Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A – single vs. repeat injections. Toxicon 2013;63:83-7.
49. American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and U.S. Food and Drug Administration clearance. Position Statement. Washington, DC: ACOG. 2016. Available from: https://www.acog.org/Clinical-Guidanceand-Publications/Position/Statements/Fractional-Laser-Treatment-of-Vulvovaginal-Atrophy-and-US-Food-and-Drug-Administration-Clearance Accessed 2021 Aug 05.
50. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology. Female sexual dysfunction: ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists, number 213. Obstetrics & Gynecology 2019 Jul;134(1):e1-18.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]